Advertisement

Biodiversity and Conservation

, Volume 16, Issue 10, pp 2789–2800 | Cite as

Linking bioprospecting with sustainable development and conservation: the Panama case

  • Thomas A. KursarEmail author
  • Catherina C. Caballero-George
  • Todd L. Capson
  • Luis Cubilla-Rios
  • William H. Gerwick
  • Maria V. Heller
  • Alicia Ibañez
  • Roger G. Linington
  • Kerry L. McPhail
  • Eduardo Ortega-Barría
  • Luz I. Romero
  • P. D. Coley
Original Paper

Abstract

The limited international resources for economic aid and conservation can only mitigate poverty and losses of biodiversity. Hence, developing nations must establish the capacity to resolve their problems. Additionally, policy-makers and donors need to obtain scientific input on issues such as global change and ecosystem services. We propose that for nations rich in biodiversity, ecosystem services derived from bioprospecting, or drug discovery, could contribute to economic development. In the case where unstudied samples are shipped abroad for research, the chances of obtaining royalties are infinitesimally small. Therefore developing nations will only realize benefits from bioprospecting through in-country research on their own biodiversity. Policy-makers and donors have failed to appreciate the value of this approach. In order to provide an example of the inherent links between conservation and sustainable economic development, we initiated a drug discovery effort in Panama that emphasizes local benefit. As much of the drug discovery process as possible is conducted in Panamanian laboratories, providing jobs dependent on intact biodiversity and enhancing local research and training. In short, research, plus the spin-offs from research, provide immediate and long-lasting benefits to Panama. The connection between conservation and development has been highlighted in publicity about the project in Panama’s urban media. This provides a constructive alternative to the perception the among the urban populace that economic development inevitably competes with conservation. In summary, our program uses biodiversity to promote human health as well as to support research capacity, economic development and conservation within Panama. The program provides an example of the widely recognized but little developed concept of bioprospecting research as an ecosystem service.

Keywords

Bioprospecting Chagas’ disease Convention on biological diversity Ecosystem services ICBG Leishmaniasis Malaria Panama Policy-makers Sustainable development 

Notes

Acknowledgements

The project was supported by funds from NIH, NSF and USDA, grant number 5 U01 TW06634–01 and STRI. Among those who have made key contributions to the Panama ICBG we acknowledge Mirei Endara, Rodrigo Tarte, Elena Lombardo, Ira Rubinoff, Eldredge Bermingham, Joshua Rosenthal, Flora Katz, Yali Hallock, Mahabir Gupta and Pablo Solis. We also acknowledge the dedicated employees of Panama’s Autoridad Nacional del Ambiente and the researchers and administrators of the University of Panama and SENACYT.

References

  1. Agnew B (2000) When pharma merges, R & D is the dowry. Science 287:1952–1953CrossRefPubMedGoogle Scholar
  2. Aide TM, Grau HR (2004) Globalization, migration and Latin American ecosystems. Science 305:1915–1916CrossRefPubMedGoogle Scholar
  3. Aldhous P (1991) ‘Hunting licence’ for drugs. Nature 353:290CrossRefGoogle Scholar
  4. Angell M (2004) The truth about the drug companies. New York Rev Books 51 July 15:52–58Google Scholar
  5. Annan K (2003) A challenge to the world scientists. Science 299:1485CrossRefPubMedGoogle Scholar
  6. Beattie A, Barthlott W, Elisabetsky E et al (2005) Chapter 10. New products and industries from biodiversity. In: Hassan R, Scholes R, Ash N (eds). Millennium ecosystem assessment, ecosystems and human well-being, vol 1. Island Press, Washington, D. CGoogle Scholar
  7. Capson TL, Coley PD, Kursar TA (1996) A new paradigm for drug discovery in tropical rainforests. Nat Biotechnol 14:1200–1202CrossRefPubMedGoogle Scholar
  8. CBD (2003) Convention on Biological Diversity. Access to genetic resources and benefit-sharing case studies. www.biodiv.org/programmes/socio-eco/benefit/cs.aspx. Cited 18 April 2007Google Scholar
  9. CGIAR (2007) Consultative Group on International Agricultural Research http://www.cgiar.org Cited 18 April 2007
  10. Coley PD, Heller MV, Aizprua R et al (2003) Use of ecological criteria in designing plant collection strategies for drug discovery. Front Ecol Environ 1:421–428CrossRefGoogle Scholar
  11. Corbett Y, Herrera L, Gonzalez J et al (2004) A novel DNA-based microfluorimetric method to evaluate antimalarial drug activity. Am J Trop Med Hyg 70:119–124PubMedGoogle Scholar
  12. Correa JE, Ríos CH, Castillo AR et al (2006) Minor alkaloids from Guatteria dumetorum with antileishmanial activity. Planta Med 72:270–272CrossRefPubMedGoogle Scholar
  13. Daily GC, Ellison K (2002) The new economy of nature: the quest to make conservation profitable. Island Press, Washington, D.CGoogle Scholar
  14. Defries RS, Bounoua L, Collatz GJ (2002) Human modification of the landscape and surface climate in the next fifty years. Global Change Biol 8:438–458CrossRefGoogle Scholar
  15. Gelb MH, Hol WGJ (2002) Drugs to combat tropical protozoan parasites. Science 297:343–344CrossRefPubMedGoogle Scholar
  16. Gollin MA (1993) The convention on biological diversity and intellectual property rights. In: Reid WV, Laird SA, Meyer CA et al (eds) Biodiversity prospecting: using genetic resources for sustainable development. World Resources Institute, Washington, D.CGoogle Scholar
  17. Gollin MA (1999) New rules for natural products research. Nat Biotechnol 17:921–923CrossRefPubMedGoogle Scholar
  18. Grifo F, Newman DJ (1997) The origins of prescription drugs. In: Grifo F, Rosenthal J (eds) Biodiversity and human health. Island Press, Washington, D.CGoogle Scholar
  19. Grifo F, Rosenthal J (1997) Biodiversity and human health. Island Press, Washington, D.CGoogle Scholar
  20. Gutiérrez M, Capson T, Guzmán HM et al (2004) L-galactose as a natural product: isolation from a marine octocoral of the first α-L-galactosyl saponin. Tetrahedron Lett 45:7833–7836CrossRefGoogle Scholar
  21. Gutiérrez M, Capson TL, Guzmán HM et al (2005a) Antiprotozoal activity against Plasmodium falciparum and Trypanosoma cruzi of aeroplysinin-1 isolated from the new sponge Aplysina chiriquensis. Pharm Biol 43:762–765CrossRefGoogle Scholar
  22. Gutiérrez M, Capson TL, Guzmán HM et al (2005b) Leptolide, a new furanocembranolide diterpene from Leptogorgia alba. J Nat Prod 68:614–616CrossRefPubMedGoogle Scholar
  23. Holmgren M, Schnitzer SA (2004) Science on the rise in developing countries. PLoS Biol 2:10–13CrossRefGoogle Scholar
  24. Horwitz SB (1992) Mechanisms of action of taxol. Trends Pharmacol Sci 13:134–136CrossRefPubMedGoogle Scholar
  25. Hussein AA, Bozzi B, Correa M et al (2003a) Bioactive constituents from three Vismia species. J Nat Prod 66:858–860CrossRefPubMedGoogle Scholar
  26. Hussein AA, Gomez B, Ramos M et al (2003b) Constituents of Hirea reclinata and their anti-HIV activity. Rev Latinoam Quim 31:5–8Google Scholar
  27. Hussein AA, Barberena I, Capson TL et al (2004) New cytotoxic naphthopyrane derivatives from Adenaria floribunda. J Nat Prod 67:451–453CrossRefPubMedGoogle Scholar
  28. Hussein AA, Barberena I, Correa M et al (2005) Cytotoxic flavonol glycosides from Triplaris cumingiana. J Nat Prod 68:231–233CrossRefPubMedGoogle Scholar
  29. Jackson JBC, Kirby MX, Berger WH et al (2001a) Historical overfishing and the recent collapse of coastal ecosystems. Science 293:629–637CrossRefPubMedGoogle Scholar
  30. Jackson RB, Carpenter SR, Dahm CN et al (2001b) Water in a changing world. Ecol Appl 11:1027–1045CrossRefGoogle Scholar
  31. Kettler HE, Modi R (2001) Building local research and development capacity for the prevention and cure of neglected diseases: the case of India. Bull World Health Organ 79:742–747PubMedGoogle Scholar
  32. Kingston DGI, Abdel-Kader M, Zhou B-N et al (1999) The suriname international cooperative biodiversity group program: lessons from the first five years. Pharm Biol 37(Supplement):22–34CrossRefGoogle Scholar
  33. Kiss A (2004) Is community-based ecotourism a good use of biodiversity conservation funds? Trends Ecol Evol 19:232–237CrossRefPubMedGoogle Scholar
  34. Koehn FE, Carter GT (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4:206–220CrossRefPubMedGoogle Scholar
  35. Kremen C (2005) Managing ecosystem services: what do we need to know about their ecology? Ecol Lett 8:468–479CrossRefGoogle Scholar
  36. Kursar TA, Capson TL, Coley PD et al (1999) Ecologically guided bioprospecting in Panama. Pharm Biol 37 (Supplement):114–126CrossRefGoogle Scholar
  37. Kursar TA, Coley PD (2003) Convergence in defense syndromes of young leaves in tropical rainforests. Biochem Syst Ecol 21:929–949CrossRefGoogle Scholar
  38. Kursar TA, Caballero-George CC, Capson TL et al (2006) Securing economic benefits and promoting conservation through bioprospecting. BioSci 56:1005–1012CrossRefGoogle Scholar
  39. Kursar TA, Capson TL, Cubilla-Rios L, et al (2007) Bioprospecting promotes conservation, enhances research capacity and provides economic uses of biodiversity. In: Schnitzler S, Carson W (eds) Tropical forest ecology, Blackwell Scientific (in press)Google Scholar
  40. Laird SA, ten Kate K (2002) Linking biodiversity prospecting and forest conservation. In: Pagiola S, Bishop J, Landell-Mills N (eds) Selling forest environmental services. Market-based mechanisms for conservation and development. Sterling, VirginiaGoogle Scholar
  41. Linington RG, Gonzalez J, Ureña L-D et al (2007) Venturamides A and B: antimalarial constituents of the Panamanian marine cyanobacterium Oscillatoria sp. J Nat Prod 70:397–401CrossRefPubMedGoogle Scholar
  42. Mani S, Macapinlac M Jr, Goel S et al (2004) The clinical development of new mitotic inhibitors that stabilize the microtubule. Anti-Cancer Drugs 15:553–558CrossRefPubMedGoogle Scholar
  43. McPhail KL, Correa J, Linington RG, et al (2007) Anti-plasmodial linear lipopeptides from a Panama strain of the marine cyanobacterium Lyngbya majuscula. J Nat Prod Web Release Date 19-Apr-2007; DOI: 10.1021/np0700772Google Scholar
  44. McShane TO, Wells MP (eds) (2004) Getting biodiversity to work: towards more effective conservation and development. Colombia University Press, New York, NYGoogle Scholar
  45. Montenegro H, Gutiérrez M, Romero LI et al (2003) Aporphine alkaloids from Guatteria spp. with leishmanicidal activity. Planta Med 69:677–679CrossRefPubMedGoogle Scholar
  46. Morel CM, Acharya T, Broun D et al (2005) Health innovation networks to help developing countries address neglected diseases. Science 309:401–404CrossRefPubMedGoogle Scholar
  47. Myers N, Kent J (2003) New consumers: The influence of affluence on the environment. Proc Natl Acad Sci USA 100:4963–4968CrossRefPubMedGoogle Scholar
  48. Neto RB, Dickson D (1999) $3m deal launches major hunt for drug leads in Brazil. Nature 400:302CrossRefGoogle Scholar
  49. Newman DJ, Cragg GM, Snader KM et al (2003) Natural products as sources of new drugs over the period 1981–2002. J Nat Prod 66:1022–1037CrossRefPubMedGoogle Scholar
  50. Newmark WD, Hough JL (2000) Conserving wildlife in Africa: integrated conservation and development projects and beyond. BioScience 50:585–592CrossRefGoogle Scholar
  51. Odling-Smee L (2005) Conservation: dollars and sense. Nature 437:614–616CrossRefPubMedGoogle Scholar
  52. Ortega-Barría E, Corbett Y, Herrera L et al (2005) Fluorescence-based bioassay for anti-parasitic drugs. In: Patent US (ed) International application published under the Patent Cooperation Treaty (PCT)Google Scholar
  53. Ospina CA, Rodriguez AD, Sanchez JA et al (2005) Caucanolides A-F, unusual antiplasmodial constituents from a Colombian collection of the gorgonian coral Pseudopterogorgia bipinnata. J Nat Prod 68:1519–1526CrossRefPubMedGoogle Scholar
  54. Paterson I, Anderson EA (2005) The renaissance of natural products as drug candidates. Science 310:451–453CrossRefPubMedGoogle Scholar
  55. Pauly D, Christensen V, Guénette S et al (2002) Towards sustainability in world fisheries. Nature 418:689–695CrossRefPubMedGoogle Scholar
  56. Plucknett DL, Smith NJH, Williams JT, Anishetty NM (1987) Gene banks and the world’s food. Princeton University Press, Princeton, New JerseyGoogle Scholar
  57. Rabalais NN, Turner RE, Wiseman Jr WJ (2002) Gulf of Mexico hypoxia, a.k.a. The Dead Zone. Annu Rev Ecol Syst 33:235–263CrossRefGoogle Scholar
  58. Ramankutty N, Foley JA (1999) Estimating historical changes in land cover: North American croplands from 1850 to 1992. Global Ecol Biogeog 8:381–396CrossRefGoogle Scholar
  59. Reid WV (2004) Bridging the science - Policy divide. PLoS Biol 2:169–171CrossRefGoogle Scholar
  60. Rosen MK, Schreiber SL (1992) Natural products as probes of cellular function: studies of immunophilins. Angew Chem Int Ed Engl 31:384–400CrossRefGoogle Scholar
  61. Rosenthal JP, Beck D, Bhat A et al (1999) Combining high-risk science with ambitious social and economic goals. Pharm Biol 37(Supplement):6–21CrossRefGoogle Scholar
  62. Rosenthal JP, Katz FN (2004) Natural products research partnerships with multiple objectives in global biodiversity hotspots: Nine years of the International Cooperative Biodiversity Groups Program. In: Bull A (ed) Microbial diversity and bioprospecting. ASM Press, Washington DC, pp 458–466Google Scholar
  63. Sachs JD, Reid WV (2006) Investments toward sustainable development. Science 312:1002CrossRefPubMedGoogle Scholar
  64. Schuster BG, Jackson JE, Obijiofor CN et al (1999) Drug development and conservation of biodiversity in West and Central Africa: A model for collaboration with indigenous people. Pharm Biol 37(Supplement):84–99CrossRefGoogle Scholar
  65. Schwartzman S, Moreira A, Nepstad D (2000) Rethinking tropical forest conservation: perils in parks. Conserv Biol 14:1351–1357CrossRefGoogle Scholar
  66. Simmons TL, McPhail KL, Ortega-Barría E et al (2006) Belamide A, a new antimitotic tetrapeptide from a Panama marine cyanobacterium. Tetrahedron Lett 47:3387–3390CrossRefGoogle Scholar
  67. Soejarto DD, Gyllenhaal C, Regalado JC et al (1999) Studies on biodiversity of Vietnam and Laos: The UIC-based ICBG program. Pharm Biol 37(Supplement):100–113CrossRefGoogle Scholar
  68. tenKate K, Laird SA (1999) The commercial use of biodiversity: access to genetic resources and benefit-sharing. Earthscan Publications Ltd., LondonGoogle Scholar
  69. Tilman D, Fargione J, Wolff B et al (2001) Forecasting agriculturally driven global environmental change. Science 292:281–284CrossRefPubMedGoogle Scholar
  70. Torres-Mendoza D, Ureña-González LD, Ortega-Barría E et al (2003) Five new cassane diterpenes from Myrospermum frutescens with activity against Trypanosoma cruzi. J Nat Prod 66:928–932CrossRefGoogle Scholar
  71. Torres-Mendoza D, Ureña-González LD, Ortega-Barría E et al (2004) Novel cassane and cleistanthane diterpenes from Myrospermum frutescens: Absolute stereochemistry of the cassane diterpene series. J Nat Prod 67:1711–1715CrossRefPubMedGoogle Scholar
  72. Trouiller P. Torreele E, Olliaro P et al (2001) Drugs for neglected diseases: a failure of the market and a public policy health failure? Trop Med Int Health 6:945–951CrossRefGoogle Scholar
  73. UNCTAD (2005) World investment report 2005. Transnational corporations and the internationalization of R & D. In: United Nations conference on trade and development (UNCTAD) United Nations, New York and GenevaGoogle Scholar
  74. United Nations (2004) World urbanization prospects: the 2003 revision. Table A.2. http://www.un.org/esa/population/publications/wup2003/WUP2003.htm. Cited 18 April 2007Google Scholar
  75. Wei X, Rodríguez A, Baran P et al (2004) Antiplasmodial cembradiene diterpenoids from a southwestern Caribbean gorgonian octocoral of the genus Eunicea. Tetrahedron Lett 60:11813–11819Google Scholar
  76. Williams C, Espinosa OA, Montenegro H et al (2003) Hydrosoluble formazan XTT: its application to natural products drug discovery for Leishmania. J Microbiol Methods 55:813–816CrossRefPubMedGoogle Scholar
  77. Willis RC (2006) e-Therapeutics takes the road to Rio. Drug Discov News December, 25–28Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2007

Authors and Affiliations

  • Thomas A. Kursar
    • 1
    • 2
    Email author
  • Catherina C. Caballero-George
    • 2
  • Todd L. Capson
    • 2
  • Luis Cubilla-Rios
    • 3
  • William H. Gerwick
    • 2
    • 4
  • Maria V. Heller
    • 2
    • 7
  • Alicia Ibañez
    • 2
  • Roger G. Linington
    • 4
    • 5
  • Kerry L. McPhail
    • 6
  • Eduardo Ortega-Barría
    • 5
  • Luz I. Romero
    • 5
  • P. D. Coley
    • 1
    • 2
  1. 1.Department of BiologyUniversity of UtahSalt Lake CityUSA
  2. 2.Smithsonian Tropical Research InstitutePanama CityRepublic of Panama
  3. 3.Department of ChemistryUniversity of PanamaPanama CityRepublic of Panama
  4. 4.Scripps Institution of OceanographyLa JollaUSA
  5. 5.Institute of Advanced Scientific Research and High TechnologyPanama CityRepublic of Panama
  6. 6.College of PharmacyOregon State UniversityCorvallisUSA
  7. 7.Secretaría Nacional de Ciencia, Tecnología e Innovación (SENACYT)Clayton, AnconRepublic of Panama

Personalised recommendations